Literature DB >> 32036606

Fibrocytes in the Tumor Microenvironment.

David Roife1,2, Jason B Fleming2, Richard H Gomer3.   

Abstract

Tumors have long been compared to chronic wounds that do not heal, since they share many of the same molecular and cellular processes. In normal wounds, healing processes lead to restoration of cellular architecture, while in malignant tumors, these healing processes become dysregulated and contribute to growth and invasion of neoplastic cells into the surrounding tissues. Fibrocytes are fibroblast-like cells that differentiate from bone marrow-derived CD14+ circulating monocytes and aid wound healing. Although most monocytes will differentiate into macrophages after extravasating into a tissue, signals present in a wound environment can cause some monocytes to differentiate into fibrocytes. The fibrocytes secrete matrix proteins and inflammatory cytokines, activate local fibroblasts to proliferate and increase extracellular matrix production, and promote angiogenesis, and because fibrocytes are contractile, they also help wound contraction. There is now emerging evidence that fibrocytes are present in the tumor microenvironment, attracted by the chronic tissue damage and cytokines from both cancer cells and other immune cells. Fibrocytes may aid in the survival and spread of neoplastic cells, so these wound-healing cells may be a promising target for anticancer research in future studies.

Entities:  

Keywords:  Benign; Cancer; Fibroblast; Fibrocyte; Fibrosis; Malignant; Metastasis; Microenvironment; Monocyte; Myofibroblast; Scar; Stroma; Tumor; Wound

Mesh:

Year:  2020        PMID: 32036606      PMCID: PMC7212529          DOI: 10.1007/978-3-030-35723-8_6

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  52 in total

1.  There is more than one kind of myofibroblast: analysis of CD34 expression in benign, in situ, and invasive breast lesions.

Authors:  H Chauhan; A Abraham; J R A Phillips; J H Pringle; R A Walker; J L Jones
Journal:  J Clin Pathol       Date:  2003-04       Impact factor: 3.411

Review 2.  Stromal biology of pancreatic cancer.

Authors:  Gerald C Chu; Alec C Kimmelman; Aram F Hezel; Ronald A DePinho
Journal:  J Cell Biochem       Date:  2007-07-01       Impact factor: 4.429

3.  Extracellular matrix stimulates reactive oxygen species production and increases pancreatic cancer cell survival through 5-lipoxygenase and NADPH oxidase.

Authors:  Mouad Edderkaoui; Peggy Hong; Eva C Vaquero; Jong K Lee; Lars Fischer; Helmut Friess; Markus W Buchler; Markus M Lerch; Stephen J Pandol; Anna S Gukovskaya
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2005-07-21       Impact factor: 4.052

4.  Extracellular matrix proteins protect pancreatic cancer cells from death via mitochondrial and nonmitochondrial pathways.

Authors:  Eva C Vaquero; Mouad Edderkaoui; Kyung J Nam; Ilya Gukovsky; Stephen J Pandol; Anna S Gukovskaya
Journal:  Gastroenterology       Date:  2003-10       Impact factor: 22.682

5.  Circulating fibrocytes prepare the lung for cancer metastasis by recruiting Ly-6C+ monocytes via CCL2.

Authors:  Hendrik W van Deventer; Daniela A Palmieri; Qing Ping Wu; Everett C McCook; Jonathan S Serody
Journal:  J Immunol       Date:  2013-03-27       Impact factor: 5.422

6.  Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4.

Authors:  M Todaro; Y Lombardo; M G Francipane; M Perez Alea; P Cammareri; F Iovino; A B Di Stefano; C Di Bernardo; A Agrusa; G Condorelli; H Walczak; G Stassi
Journal:  Cell Death Differ       Date:  2008-01-18       Impact factor: 15.828

7.  Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins.

Authors:  Hidenori Miyamoto; Tatsuya Murakami; Kunihiro Tsuchida; Hiromu Sugino; Hidenori Miyake; Seiki Tashiro
Journal:  Pancreas       Date:  2004-01       Impact factor: 3.327

8.  Basement membrane proteins play an important role in the invasive processes of human pancreatic cancer cells.

Authors:  Hirozumi Sawai; Yuji Okada; Hitoshi Funahashi; Hiroki Takahashi; Yoichi Matsuo; Akira Yasuda; Nobuo Ochi; Hiromitsu Takeyama; Tadao Manabe
Journal:  J Surg Res       Date:  2007-08-03       Impact factor: 2.192

9.  Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer.

Authors:  Hua Zhang; Irena Maric; Michael J DiPrima; Javed Khan; Rimas J Orentas; Rosandra N Kaplan; Crystal L Mackall
Journal:  Blood       Date:  2013-06-11       Impact factor: 22.113

10.  Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab.

Authors:  Atsushi Mitsuhashi; Hisatsugu Goto; Atsuro Saijo; Van The Trung; Yoshinori Aono; Hirokazu Ogino; Takuya Kuramoto; Sho Tabata; Hisanori Uehara; Keisuke Izumi; Mitsuteru Yoshida; Hiroaki Kobayashi; Hidefusa Takahashi; Masashi Gotoh; Soji Kakiuchi; Masaki Hanibuchi; Seiji Yano; Hiroyasu Yokomise; Shoji Sakiyama; Yasuhiko Nishioka
Journal:  Nat Commun       Date:  2015-12-04       Impact factor: 14.919

View more
  4 in total

1.  Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy.

Authors:  Roshini Fernando; Oshadi Caldera; Terry J Smith
Journal:  Proc Natl Acad Sci U S A       Date:  2021-12-28       Impact factor: 12.779

2.  Irbesartan, an angiotensin II type 1 receptor blocker, inhibits colitis-associated tumourigenesis by blocking the MCP-1/CCR2 pathway.

Authors:  Kensuke Hachiya; Masahiro Masuya; Naoki Kuroda; Misao Yoneda; Junya Tsuboi; Keiki Nagaharu; Komei Nishimura; Takuya Shiotani; Kohshi Ohishi; Isao Tawara; Naoyuki Katayama
Journal:  Sci Rep       Date:  2021-10-07       Impact factor: 4.379

3.  Analysis of the chemotactic factors for tumor-infiltrating fibrocytes and their prognostic significances in lung cancer.

Authors:  Makoto Tobiume; Atsushi Mitsuhashi; Atsuro Saijo; Hirokazu Ogino; Tania Afroj; Hirohisa Ogawa; Hisatsugu Goto; Seidai Sato; Akane Abe; Keiko Haji; Ryohiko Ozaki; Hiromitsu Takizawa; Yasuhiko Nishioka
Journal:  Oncol Lett       Date:  2022-09-30       Impact factor: 3.111

Review 4.  The Blood Circulating Rare Cell Population. What is it and What is it Good For?

Authors:  Stefan Schreier; Wannapong Triampo
Journal:  Cells       Date:  2020-03-25       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.